---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-25-000004"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:06:07.845059+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q4 revenue down 2%; launches restructuring (5% workforce cut) and offers to acquire Stilla

## Summary
- Q4 2024 revenue $667.5M vs $681.2M YoY; GAAP operating income $58.4M vs $95.3M.
- Full-year 2024 revenue $2,566.5M vs $2,671.2M; non-GAAP op margin 12.9% vs 14.2%.
- Restructuring plan eliminates ~5% of workforce; expected cost $45-50M, $30-35M charge in Q1 2025.
- Binding offer to acquire all equity of Stilla Technologies (digital PCR); close expected by Q3 2025.
- No deal value disclosed; acquisition subject to regulatory approvals and employee consultation.

## SEC filing metadata
- accession: 0000012208-25-000004
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220825000004/0000012208-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220825000004/bio-20250207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-25-000004
- JSON: https://secwatch.observer/filing/0000012208-25-000004.json
- Plain text: https://secwatch.observer/filing/0000012208-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.